https://quantalx.com/neurosense-and-quantalx-collaborate-to-improve-early-detection-and-treatment-of-neurodegenerative-diseases/ 2023-02-20T12:04:35+00:00 http://quantalx.com/wp-content/uploads/2023/02/NeuroSense_and_QuantalX.jpg http://quantalx.com/wp-content/uploads/2023/02/NeuroSense_and_QuantalX.jpg https://quantalx.com/test-4/ 2023-02-23T13:19:12+00:00 https://quantalx.com/imio-partners-with-quantalix-to-map-brain-network-response-to-psychedelic-therapy/ 2023-03-18T13:17:19+00:00 https://quantalx.com/quantalx-receives-fda-breakthrough-designation-for-diagnosis-of-normal-pressure-hydrocephalus-and-prediction-of-treatment-response/ 2023-06-01T12:57:37+00:00 https://quantalx.com/quantalx-secures-dedicated-reimbursement-code-for-delphi-md-test-advancing-improved-brain-health/ 2023-11-05T16:09:57+00:00 https://quantalx.com/quantalx-secures-spot-in-fdas-prestigious-total-life-cycle-advisory-program-tap/ 2024-04-11T13:10:37+00:00 https://quantalx.com/quantalx-partners-with-sheba-longevity-center-to-advance-brain-health-across-lifespan/ 2024-05-21T15:36:37+00:00 https://quantalx.com/wp-content/uploads/2024/05/QuantalX_Sheba.jpg https://quantalx.com/quantalx-partners-with-the-university-of-illinois-chicago-towards-successful-us-commercialization/ 2024-06-06T07:35:09+00:00 http://quantalx.com/wp-content/uploads/2024/06/QX-PR-Pic-UIC-V4.jpg https://quantalx.com/delphi-md-revolutionizes-parkinsons-differential-diagnosis/ 2024-10-30T10:57:13+00:00 http://quantalx.com/wp-content/uploads/2024/10/QX-PR-Pic-Oct2024-V1.jpg https://quantalx.com/exploring-new-frontiers-in-parkinsons-research-our-journey/ 2025-01-28T06:23:54+00:00 https://quantalx.com/empowering-healthy-aging-the-importance-of-early-detection-for-brain-health/ 2025-01-28T06:26:01+00:00 https://quantalx.com/unmasking-the-hidden-struggle-mild-cognitive-impairment-and-the-urgent-need-for-early-detection/ 2025-01-28T06:27:04+00:00 https://quantalx.com/a-remarkable-week-at-jpm-2025/ 2025-01-28T10:08:31+00:00 https://quantalx.com/quantalx-neuroscience-announces-ce-mdr-approval-making-brain-health-assessment-available-in-the-eu/ 2025-02-12T13:37:57+00:00 http://quantalx.com/wp-content/uploads/2025/02/QuantalX_Delphi_MD-press-release.jpg https://quantalx.com/quantalx-secures-fda-clearance-for-its-breakthrough-delphi-stimulator-advancing-direct-brain-health-diagnosis-at-the-point-of-care/ 2025-03-26T13:58:27+00:00 https://quantalx.com/our-brain-in-action/ 2025-12-01T17:05:17+00:00 https://quantalx.com/breaking-the-barrier-between-research-and-practice-real-time-brain-function-imaging-comes-to-the-clinic/ 2026-01-11T14:10:16+00:00 https://quantalx.com/quantalx-receives-fda-de-novo-clearance-for-delphi-md-establishing-a-new-modality-of-brain-function-assessment/ 2026-02-16T14:12:35+00:00 https://quantalx.com/quantalx-neuroscience-announces-us-commercialization-of-delphimd-following-fda-de-novo-classification/ 2026-02-18T14:01:13+00:00